Contrasting Tandem Diabetes Care (NASDAQ:TNDM) & Solventum (NYSE:SOLV)

Solventum (NYSE:SOLV) and Tandem Diabetes Care (NASDAQ:TNDM) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, analyst recommendations and risk.

Risk and Volatility

Solventum has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500. Comparatively, Tandem Diabetes Care has a beta of 1.66, indicating that its share price is 66% more volatile than the S&P 500.

Profitability

This table compares Solventum and Tandem Diabetes Care’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Solventum	17.26%	25.09%	8.78%
Tandem Diabetes Care	-6.08%	-45.97%	-6.23%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Solventum and Tandem Diabetes Care, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solventum	1	3	8	0	2.58
Tandem Diabetes Care	1	11	10	1	2.48

Solventum presently has a consensus target price of $92.80, indicating a potential upside of 5.48%. Tandem Diabetes Care has a consensus target price of $29.13, indicating a potential upside of 76.56%. Given Tandem Diabetes Care’s higher possible upside, analysts clearly believe Tandem Diabetes Care is more favorable than Solventum.

Earnings and Valuation

This table compares Solventum and Tandem Diabetes Care”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solventum	$8.32 billion	1.80	$1.56 billion	$8.18	10.76
Tandem Diabetes Care	$1.01 billion	1.13	-$204.71 million	($0.93)	-17.74

Solventum has higher revenue and earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks.

Summary

Solventum beats Tandem Diabetes Care on 9 of the 13 factors compared between the two stocks.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.